bioMérieux presents its new 5-year strategic plan and its targets for profitable growth

Marcy l’Étoile, France, April 9, 2024 – bioMérieux, a world leader in the field in vitro diagnostics, is hosting today a Capital Markets Day in Paris. On this occasion, Pierre Boulud, Chief Executive Officer, together with members of the Executive Committee will present bioMérieux’s strategic plan, GO•28, the new chapter for the Company’s growth and development.

Pierre Boulud, Chief Executive Officer, said: “bioMérieux has delivered a remarkable performance over the last few years and is emerging from the COVID-19 period stronger and more diversified. With the GO•28 plan, we are presenting today an ambitious medium term strategy for profitable and sustainable growth to better serve our purpose to help make the world a healthier place.”

bioMérieux’s strategy is composed of four dimensions:

• to pursue its strong organic growth, building on its comprehensive portfolio of solutions further supported by continuous innovation,
• to simplify its operating model to increase its efficiency and profitability,
• to act responsibly for the benefit of its team members, patients, consumers and the planet
• to grow stronger and more agile as an organization by empowering and engaging all team members.

Assuming no significant change to the current market environment, with the GO•28 plan, bioMérieux aims to reach the following targets:

• Organic revenue growth¹ of +7%, CAGR² 2024 / 2028
• Contributive Operating Income before non recurring items³ improving to 20% of sales in 2028 at constant exchange rates and scope (from 16.5% in 2023), with an annual organic increase of at least 10% per year until 2028
• Annual Capex: around 8 to 10% of annual sales for the period 2025 / 2028
• Dividend pay-out ratio policy of around 25% of the annual Group net income
• Renewed commitment to deliver on the Corporate Social Responsibility strategy and notably an ambitious -50% decrease in GHG absolute emissions in 2030 vs. 2019 for scope 1&2

¹ Organic growth corresponds to year-on-year sales growth at constant scope and currencies and excludes the impact of hyperinflation,    recognized in accordance with IAS 29.

² Compound Annual Growth Rate

³ Contributive operating income before non-recurring items corresponds to operating income excluding amortization and impairment of intangible assets related to acquisitions and acquisition-related costs